Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects

Leukemia and Lymphoma

Volumn 52, Issue 9, 2011, Pages 1742-1750

  Riera, Ludovica ^a   Lasorsa, Elena ^a   Bonello, Lisa ^a   Sismondi, Francesca ^a   Tondat, Fabrizio ^a   Di Bello, Cristiana ^a   Di Celle, Paola Francia ^a   Chiarle, Roberto ^a   Godio, Laura ^b   Pich, Achille ^a   Facchetti, Fabio ^c   Ponzoni, Maurilio ^d   Marmont, Filippo ^b   Zanon, Carlo ^a   Bardelli, Alberto ^a   Inghirami, Giorgio ^a,e  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AML; Janus kinase; mutation

Indexed keywords

JANUS KINASE 3;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; GERM LINE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ORDER; HEK293 CELLS; HUMANS; JANUS KINASE 3; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; MUTATION; NIH 3T3 CELLS;

EID: 80052062979     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.574757     Document Type: Article

References (42)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33:451-458.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
3. Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008;35:388-400.
4. Scholl S, Fricke HJ, Sayer HG, Hoffken K. Clinical implications of molecular genetic aberrations in acute myeloid leukemia. J Cancer Res Clin Oncol 2009;135:491-505.
5. Marcucci G, Mrozek K, Bloomfield CD. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005;12:68-75. (Pubitemid 40192577)
6. Loriaux MM, Levine RL, Tyner JW, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008;111:4788-4796.
7. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E. Regulation of constitutive STAT5 phosphoryla-tion in acute myeloid leukemia blasts. Leukemia 2001;15:1923-1931. (Pubitemid 33115000)
8. Inghirami G, Szabolcs MJ, Yee HT, Corradini P, Cesarman E, Knowles DM. Detection of immunoglobulin gene rearrangement of B cell non-Hodgkin's lymphomas and leukemias in fresh, unfixed and formalin-fixed, paraffin-embedded tissue by polymerase chain reaction. Lab Invest 1993;68:746-757. (Pubitemid 23202803)
9. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-1928.
10. Grignani F, Kinsella T, Mencarelli A, et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 1998;58:14-19. (Pubitemid 28027708)
11. Voena C, Conte C, Ambrogio C, et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res 2007;67:4278-4286. (Pubitemid 46815075)
12. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
13. Flores-Morales A, Pircher TJ, Silvennoinen O, et al. In vitro interaction between STAT 5 and JAK 2; dependence upon phosphorylation status of STAT 5 and JAK 2. Mol Cell Endocrinol 1998;138:1-10. (Pubitemid 28302012)
14. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hemato-poietic precursor cells. Exp Hematol 2002;30:262-271. (Pubitemid 34203733)
15. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002;277:47954-47963. (Pubitemid 36159324)
16. Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005;46:247-255. (Pubitemid 40185956)
17. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-598.
18. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000;95:1056-1065. (Pubitemid 30062731)
19. Nakamura Y, Ito M, Yamamoto T, et al. Engraftment of NOD/SCID/ gammac(null) mice with multilineage neoplastic cells from patients with juvenile myelomonocytic leukaemia. Br J Haematol 2005;130:51-57. (Pubitemid 40979132)
20. Carver BS, Pandolfi PP. Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 2006;12:5305-5311. (Pubitemid 44497243)
21. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008;19:385-393.
22. Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007;21: 574-576.
23. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000;14:1766-1776.
24. Dobbin E, Graham C, Corrigan PM, Thomas KG, Freeburn RW, Wheadon H. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways. Exp Hematol 2009;37:111-121.
25. Cain JA, Xiang Z, O'Neal J, et al. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood 2007;109:3906-3914. (Pubitemid 46641743)
26. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000;96:2269-2276.
27. Ye D, Wolff N, Li L, Zhang S, Ilaria RL Jr. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 2006;107:4917-4925. (Pubitemid 43882645)
28. Tortolani PJ, Lal BK, Riva A, et al. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J Immunol 1995;155:5220-5226.
29. Brown MP, Nosaka T, Tripp RA, et al. Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. Blood 1999;94:1906-1914. (Pubitemid 29430406)
30. Johnston JA, Kawamura M, Kirken RA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994;370:151-153. (Pubitemid 24229128)
31. Miyazaki T, Kawahara A, Fujii H, et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994;266:1045-1047. (Pubitemid 24373722)
32. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993;73:147-157. (Pubitemid 23115456)
33. Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science 1995;270:800-802.
34. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005;203:127-142. (Pubitemid 40179698)
35. Russell SM, Johnston JA, Noguchi M, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 1994;266:1042-1045.
36. Sohn SJ, Forbush KA, Nguyen N, et al. Requirement for Jak3 in mature T cells: its role in regulation of T cell homeostasis. J Immunol 1998;160:2130-2138. (Pubitemid 28119891)
37. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995;270:794-797.
38. Witthuhn BA, Silvennoinen O, Miura O, et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994;370:153-157. (Pubitemid 24229129)
39. Sato T, Toki T, Kanezaki R, et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br J Haematol 2008;141:681-688. (Pubitemid 351667619)
40. De Vita S, Mulligan C, McElwaine S, et al. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome. Br J Haematol 2007;137:337-341. (Pubitemid 46650253)
41. Malinge S, Ragu C, Della-Valle V, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008;112: 4220-4226.
42. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009;106:9414-9418.